D-0334-2023 Class II Terminated

Recalled by IBSA PHARMA INC — Parsippany, NJ

FDA drug recall D-0334-2023 was initiated by IBSA PHARMA INC on Jan 30, 2023 and is designated Class II. Reason for recall: Subpotent Drug The recall status is terminated (terminated Oct 31, 2023).

Recall details

Product Type
Drugs
Report Date
Mar 1, 2023
Initiation Date
Jan 30, 2023
Termination Date
Oct 31, 2023
Voluntary/Mandated
Voluntary: Firm initiated

Product description

TIROSINT - SOL (levothyroxine sodium) Oral Solution, 175 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0155-5

Reason for recall

Subpotent Drug

Distribution pattern

Nationwide in the USA.

Code information

Lot #: 220416, Exp. 10/2023; 221053, Exp. 4/2024.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0334-2023
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0334-2023. Report a data issue: hello@regdatalab.com.